AMRN
Amarin Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Market Cap: 93.8 Million
Primary Exchange: NASDAQ
Website: http://www.amarincorp.com/
Shares Outstanding: 98.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.9965183819887526
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1422 trading days
From: 2013-01-17 To: 2018-09-21
Lowest Point:
Amarin Corporation plc (AMRN) CEO John Thero Presents at Goldman Sachs 40th Annual Global Healthcare Conference (Transcript)
via: SeekingAlpha at 2019-06-12 17:43:08:000
Amarin Corporation plc (AMRN) Goldman Sachs 40th Annual Global Healthcare Conference Call June 12, 2019 4:20 P.M. ET Company Participants John Thero - President and Chief Executive Officer Conference Call Participants Presentation John Thero Hello, everybody. Thank you … read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Upon Vascepa Expanded Label, The Landscape For Cardiovascular Disease Would Greatly Change
via: SeekingAlpha at 2019-06-11 16:54:13:000
Amarin ( AMRN ) is having good fortune, especially when it comes to its supplemental new drug application (sNDA) for its drug Vascepa. That's because the biotech is seeking to expand the label for approval of its drug to reduce cardiovascular risk for patients with statin-managed LDL-C chole… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|